Impact News +++ Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a... (GlobeNewswire EN) +++ CARDIFF ONCOLOGY Aktie +4,53%

REGENERON Aktie

>REGENERON Aktienkurs

632.7 EUR -0.1% (TradegateBSX)

Ask: 640.1 EUR / 15 Stück

Bid: 635.5 EUR / 15 Stück

Tagesumsatz: 171 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REGENERON Aktie über LYNX handeln

Intraday

1 Jahr

>REGENERON Performance

1 Woche: +0,1%

1 Monat: -4,2%

3 Monate: +0,1%

6 Monate: +28,6%

1 Jahr: +28,3%

laufendes Jahr: -4,6%

>REGENERON Aktie

Name:

REGENERON PHARMAC.DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US75886F1075 / 881535

Symbol/ Ticker:

RGO (Frankfurt) / REGN (NASDAQ)

Kürzel:

FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN

Index:

S&P500, Nasdaq100

Webseite:

http://www.regeneron.com/

Profil:

Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company operates across multiple therapeutic areas, with flagship products including Eylea and Eylea HD for eye dis..
>Volltext..

Marktkapitalisierung:

67439.84 Mio. EUR

Unternehmenswert:

62633.73 Mio. EUR

Umsatz:

12192.04 Mio. EUR

EBITDA:

3609.02 Mio. EUR

Nettogewinn:

3829.35 Mio. EUR

Gewinn je Aktie:

36.65 EUR

Schulden:

2526.91 Mio. EUR

Liquide Mittel:

2655.27 Mio. EUR

Operativer Cashflow:

4232.26 Mio. EUR

Bargeldquote:

1.97

Umsatzwachstum:

-10.98%

Gewinnwachstum:

-10.02%

Dividende je Aktie:

3.19 EUR

Dividendenrendite:

0.48%

Dividendenschätzung:

0.5%

Div. Historie:

20.02.26 - 0.798906€
20.11.25 - 0.76287204€

>weitere anzeigen...

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 77.727 USD.

Suchwörter:

REGENERON

Letzte Datenerhebung:

18.04.26

>REGENERON Kennzahlen

Aktien/ Unternehmen:

Aktien: 103.9 Mio. St.

Frei handelbar: 97.93%

Leerverk. Aktien: 2.45%

Rückkaufquote: 3.53%

Mitarbeiter: 15410

Umsatz/Mitarb.: 0.79 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 19.28%

Bewertung:

KGV: 17.74

KGV lG: 16.32

KUV: 5.61

KBV: 2.49

PEG-Ratio: 2.1

EV/EBITDA: 17.35

Rentabilität:

Bruttomarge: 81.56%

Gewinnmarge: 31.41%

Operative Marge: 25.81%

Managementeffizenz:

Gesamtkaprendite: 11.49%

Eigenkaprendite: 14.87%

>REGENERON Peer Group

Gesundheit, Augenmedizin, Lungenerkrankungen & -behandlung/ Asthma, Hauterkrankungen & -behandlung/ Dermatologie, Onkologie/ Krebs- Behandlung, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Herz-Kreislauf- Behandlung/ Kardiologie

>REGENERON Chart & Kurs - NASDAQ

>REGENERON News

17.04.26 - 17:24

XETR: Deletion of Instruments from XETRA - 17.04.2026 -2- (XETRA)

The following instruments on XETRA do have their last trading day on 17.04.2026. Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026. ISIN Name US5719032022 Marriott International Inc. US57667L1070 Match Group Inc. US59156R1086 MetLife Inc. US5926881054 Mettler-Toledo International Inc. US5950171042 Microchip Technology Inc. US6200763075 Motorola Solutions Inc. US64110D1046 NetApp Inc. US6293775085 NRG Energy Inc. NL0009538784 NXP Semiconductors NV US6819191064 Omnicom Group Inc. US68902V1070 Otis Worldwide Corp. US6937181088 PACCAR Inc. US7043261079 Paychex Inc. US69331C1080 PG & E Corp. US7185461040 Phillips 66 US69351T1060 PPL Corp. US69370C1009 PTC Inc. GB00BY2Z0H74 Puretech Health PLC US7512121010 Ralph Lauren Corp. US75886F1075 Regeneron Pharmaceuticals Inc. US74967X1037 RH US7739031091 Rockwell Automation Inc. DK0063855168 Rockwool A/S US77543R1023 Roku Inc. US7782961038 Ross Stores Inc. US8168511090 Sempra US83088M1027 Skyworks Solutions...

15.04.26 - 16:00	Inside Biotech: Telix rally meets reality check as $600m raise tempers Regeneron-driven surge (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

14.04.26 - 20:30	Regeneron Boosts Cancer Pipeline Through Telix Collaboration (Zacks)
	Regeneron teams up with Telix in a 50/50 radiopharma deal, betting on next-gen cancer therapies to expand its oncology pipeline and long-term growth....

14.04.26 - 14:36	Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report (Barchart)
	Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

13.04.26 - 14:33	Regeneron inks deal with Telix for radiopharmaceutical therapies (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.04.26 - 13:18	Regeneron Pharma Partners Telix Pharma To Jointly Develop Radiopharmaceutical Therapies (AFX)
	CANBERA (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Telix Pharmaceuticals Ltd. (TLX, TLX.AX) announced Monday a collaboration to jointly develop and commercialize next generation radiop......

13.04.26 - 13:00	Telix and Regeneron to co-develop radiopharmaceutical therapies (PBR)
	Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix's expertise in radiopharmaceutical platforms, global The post Telix and Regeneron to co-develop radiopharmaceutical therapies appeared first on Pharmaceutical Business review....

13.04.26 - 12:39	Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU (Dow Jones)
	Von Colin Kellaher DOW JONES--Regeneron Pharmaceuticals und Sanofi haben für ihren Blockbuster-Entzündungshemmer Dupixent eine erweiterte europäische Zulassung für jüngere Patienten erhalten, ......

13.04.26 - 12:33	Telix and Regeneron Announce Strategic Radiopharma Collaboration (GlobeNewswire EN)
	MELBOURNE, Australia and INDIANAPOLIS and TARRYTOWN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN, “Regeneron”) today announce a collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies....

13.04.26 - 12:33	Regeneron and Telix Announce Strategic Radiopharma Collaboration (GlobeNewswire EN)
	Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model ...

13.04.26 - 08:01	Regeneron, Sanofi Secure EU Nod To Expand Dupixent Use In Young Children With CSU (AFX)
	PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi SA (SNY) on Monday said the European Commission has approved Dupixent for treating moderate-to-severe chronic spontaneous urtica......

13.04.26 - 07:03	Press Release: Sanofi and Regeneron′s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria (GlobeNewswire EN)
	Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria...

13.04.26 - 05:54	Telix And Regeneron Partner To Advance Next-Generation Radiopharmaceutical Therapies (AFX)
	CANBERA (dpa-AFX) - Telix Pharmaceuticals Limited (TLX, TLX.AX) and Regeneron Pharmaceuticals, Inc. (REGN) have announced a collaboration to jointly develop and commercialize next-generation radio......

13.04.26 - 01:24	Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal (Fool)
	Telix Pharmaceuticals has announced a US$40m strategic collaboration with Regeneron for innovative radiopharmaceutical cancer therapies. The post Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal appeared first on The Motley Fool Australia....

09.04.26 - 16:18	A catalyst-rich biotech may be poised to resume its recovery. Use options to take advantage (CNBC)
	Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas....

08.04.26 - 13:36	Regeneron expects ~$102M in Q1 pre-tax IPR&D charges (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.04.26 - 22:46	Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval (Zacks)
	REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales....

06.04.26 - 19:45	All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy (Zacks)
	Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

05.04.26 - 01:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 77727 USD (Insiderkauf)
	Ryan, Arthur F. - Aufsichtsrat - Tag der Transaktion: 2026-04-01...

03.04.26 - 19:45	Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
	Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: In Fährden ist das höchste Gut die Kühnheit. - In rebus dubiis plurimi est audacia. - Publilius Syrus

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram